Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

UCB, Biogen form MS pact

October 9, 2006 | A version of this story appeared in Volume 84, Issue 41

UCB and Biogen Idec have formed a collaboration to develop and commercialize the UCB drug CDP323 for the treatment of relapsing-remitting multiple sclerosis. CDP323 is a small-molecule α4 integrin inhibitor expected to enter Phase II clinical trials next year. Under the deal, UCB will receive upfront and other payments in excess of $200 million. Biogen's main drug, Avonex, is an MS treatment.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.